No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed RTD Sensitive: A1 - Approval cisplatin + pemetrexed RTD Sensitive : A1	cisplatin + pemetrexed RTD Sensitive: A1 - Approval cisplatin + pemetrexed RTD Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	pralatrexate Sensitive: A1 - Approval pralatrexate Sensitive : A1	pralatrexate Sensitive: A1 - Approval pralatrexate Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1	methotrexate Sensitive: A1 - Approval methotrexate Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Malignant Pleural Mesothelioma	No biomarker	Malignant Pleural Mesothelioma	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2	cytarabine + methotrexate Sensitive: A2 - Guideline cytarabine + methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Burkitt Lymphoma	No biomarker	Burkitt Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Thymic Carcinoma	No biomarker	Thymic Carcinoma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Thymoma	No biomarker	Thymoma	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2	cytarabine + methotrexate + idarubicin Sensitive: A2 - Guideline cytarabine + methotrexate + idarubicin Sensitive : A2
No biomarker	Childhood B Acute Lymphoblastic Leukemia	No biomarker	Childhood B Acute Lymphoblastic Leukemia	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2	cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive: A2 - Guideline cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2	pemetrexed Sensitive: A2 - Guideline pemetrexed Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + methotrexate Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2	ifosfamide + methotrexate + etoposide oral Sensitive: A2 - Guideline ifosfamide + methotrexate + etoposide oral Sensitive : A2

THF dehydrogenase inhibitor

THF dehydrogenase inhibitor

Associations(98)

Associations
(98)